E. Ohman J:or Asset Management AB purchased 18,686 shares of Thermo Fisher Scientific for an estimated trade size of $8.70 million. This transaction now accounts for 0.2% of the fund’s assets under management, with a post-trade position of 104,361 shares valued at $50.62 million as of September 30, 2025.

The purchase of Thermo Fisher Scientific represents 1.19% of the fund’s U.S. equity holdings, positioning it outside the top five holdings. The stock price on October 16, 2025, was $536.78, down 9.3% over the past year. The company reported revenue of $43.21 billion and net income of $6.58 billion as of June 28, 2025.

Thermo Fisher Scientific provides critical tools and services for scientific research, diagnostics, and drug development on a global scale. The company generates revenue through the sale of various products and services to pharmaceutical, biotechnology, clinical, academic, government, and industrial customers worldwide.

Despite recent stock price fluctuations, Thermo Fisher Scientific remains a strong player in the life sciences industry. With revenue exceeding $43 billion over the past twelve months, the company’s solid fundamentals and diversified portfolio position it for continued growth and success in the market.

Read more at Nasdaq: Thermo Fisher’s Pullback Is Setting Up Its Next Phase of Growth